Back

Corrigendum to: Annual adverse event profiles after clopidogrel, prasugrel, and ticagrelor in the Food and Drug Administration Adverse Event Reporting System

European Heart Journal - Cardiovascular Pharmacotherapy

19 March 2018
Organised by: Logo
Read full article
ESC Journals
You may be interested in
thumbnail
Congress Presentation
Comparative safety and effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndrome. An on treatment analysis from the multicenter CREA ARIAM Andalucia registry
19 March 2022
thumbnail
Congress Presentation
Efficacy and safety of clopidogrel, ticagrelor, and prasugrel in an all-comers population of patients with ST-segment elevation myocardial infarction
31 August 2020
thumbnail
Congress Presentation
Atrial fibrillation in patients with acute coronary syndrome under clopidogrel versus ticagrelor.
13 March 2021
thumbnail
Congress Presentation
Real world outcomes for clopidogrel versus ticagrelor treated patients with acute coronary syndrome: a systematic literature review and meta-analysis
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources